Skip to main content

Table 2 Diabetes medication by gender and prevalent coronary heart disease

From: Gender disparities in diabetes and coronary heart disease medication among patients with type 2 diabetes: results from the DIANA study

Medication of interest   With coronary heart disease Without coronary heart disease
  Men Women Men Women Men Women
  (n = 624) (n = 522) (n = 147) (n = 67) (n = 477) (n = 455)
  n % n % n % n % n % n %
Number of diabetes medication (mean, STD*) 1.3 (1.1) 1.3 (1.2) 1.5 (1.3) 1.4 (1.1) 1.3 (1.1) 1.2 (1.2)
Number of diabetes medication            
0 138 22.3 158 30.4 27 18.5 15 22.7 111 23.5 143 31.6
1 245 39.6 175 33.7 50 34.3 22 33.3 195 41.2 153 33.8
2 159 25.7 113 21.8 46 31.5 17 25.8 113 23.9 96 21.2
3 and more 77 12.4 73 14.1 23 15.7 12 18.2 54 11.4 61 13.5
Biguanide 343 55.0 273 52.3 70 47.6 35 52.2 273 57.2 238 52.3
Sulfonylurea 132 21.2 92 17.6 32 21.8 14 20.9 100 21.0 78 17.1
Alpha-glucosidase inhibitor 14 2.2 13 2.5 5 3.4 1 1.5 9 1.9 12 2.6
Thiazolidinedione 39 6.3 19 3.6 11 7.5 3 4.5 28 5.9 16 3.5
Glinide 21 3.4 13 2.5 6 4.1 1 1.5 15 3.1 12 2.6
Glucagon-like peptide-I analogue (GLP-I) exenatide 6 1.0 5 1.0 4 2.7 0 0 2 0.4 5 1.1
Dipeptidyl peptidase-4 (DPP-4) inhibitor 20 3.2 28 5.4 7 3.3 4 6.0 17 3.6 24 5.3
Oral combination drug 26 4.2 9 1.7 6 4.1 1 1.5 20 4.2 8 1.8
Insulin treatment 123 19.8 107 20.5 43 29.7 20 29.8 80 16.8 87 19.1
Short acting insulin 47 7.5 40 7.7 16 10.9 7 10.4 31 6.5 33 7.3
Intermediate acting (basal insulin) 53 8.5 56 10.7 19 12.9 10 14.9 34 7.1 46 10.1
Human insulin combination (short and intermediate acting) 22 3.5 14 2.7 8 5.4 4 6.0 14 2.9 10 2.2
Insulin analogue 58 9.3 43 8.2 22 15.0 8 11.9 36 7.5 35 7.7
  1. *SD = standard deviation. Number may not always add up to total because of missing values for some items.
  2. Significant results (p < 0.05) by χ²-test are printed bold.